Angela To
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Angela To has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Marson
University of California, San Francisco 1 Department of Medicine San Francisco, California
3 shared publications - Justin Eyquem
Department of Medicine, University of California San Francisco, San Francisco, USA
3 shared publications - Ralf Schmidt
Gladstone–UCSF Institute of Genomic Immunology, San Francisco, USA
3 shared publications - William A. Nyberg
University of California, San Francisco 1 Department of Medicine San Francisco, California
3 shared publications Zhongmei Li
3 shared publications- Chun Jimmie Ye
Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
2 shared publications
Latest Publications
- 15 August 2026
- Published by Springer Nature in Neuropsychopharmacology
- p. 1-2
Epigenomic priming of microglia bridges psychopathology and late-life cognitive decline
- 15 August 2026
- Published by Springer Nature in Neuropsychopharmacology
- p. 1-2
Epigenomic priming of microglia bridges psychopathology and late-life cognitive decline
- Open Access
Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function
Natural killer (NK) cells are emerging as a promising platform for engineered adoptive cell therapies. However, gene editing in NK cells remains challenging, and more effective strategies are needed. Here, we established a robust, feeder-free, and modular workflow for genome engineering in primary human NK cells, combining CRISPR/Cas9 with AAV6-mediated transgene delivery. Efficient site-specific transgene integration was achieved at various loci and can be coupled with concurrent disruption of the target locus in a single editing step. Furthermore, transgene expression was tunable according to the integration site and promoter. We applied this strategy to target a chimeric antigen receptor (CAR) transgene to a panel of inhibitory NK receptor loci, establishing a synergistic approach to enhance anti-tumor activity and facilitate the reliable comparison of CAR variants without expression bias. We identified TIGIT as an ideal locus that supports strong CAR expression and anti-tumor function. This genome engineering framework, which leverages multiple, complementary and precisely controlled genetic edits, can support the rational design of future NK-cell therapies tailored to overcome cell-intrinsic limitations and tumor-specific barriers.
Open AccessSite-specific genome engineering of primary human natural killer cells for programmable anti-tumor function
Natural killer (NK) cells are emerging as a promising platform for engineered adoptive cell therapies. However, gene editing in NK cells remains challenging, and more effective strategies are needed. Here, we established a robust, feeder-free, and modular workflow for genome engineering in primary human NK cells, combining CRISPR/Cas9 with AAV6-mediated transgene delivery. Efficient site-specific transgene integration was achieved at various loci and can be coupled with concurrent disruption of the target locus in a single editing step. Furthermore, transgene expression was tunable according to the integration site and promoter. We applied this strategy to target a chimeric antigen receptor (CAR) transgene to a panel of inhibitory NK receptor loci, establishing a synergistic approach to enhance anti-tumor activity and facilitate the reliable comparison of CAR variants without expression bias. We identified TIGIT as an ideal locus that supports strong CAR expression and anti-tumor function. This genome engineering framework, which leverages multiple, complementary and precisely controlled genetic edits, can support the rational design of future NK-cell therapies tailored to overcome cell-intrinsic limitations and tumor-specific barriers.
- Open Access
Modular pooled discovery of synthetic knockin sequences to program durable cell therapies
- Open Access
Modular Pooled Discovery of Synthetic Knockin Sequences to Program Durable Cell Therapies
SUMMARY: Chronic stimulation can cause T cell dysfunction and limit efficacy of cellular immunotherapies. CRISPR screens have nominated gene targets for engineered T cells, but improved methods are required to compare large numbers of synthetic knockin sequences to reprogram cell functions. Here, we developed Modular Pooled Knockin Screening (ModPoKI), an adaptable platform for modular construction of DNA knockin libraries using barcoded multicistronic adaptors. We built two ModPoKI libraries of 100 transcription factors (TFs) and 129 natural and synthetic surface receptors. Over 20 ModPoKI screens across human TCR and CAR T cells in diverse conditions identified a transcription factor AP4 (TFAP4) construct to enhance long-term T cell fitness and anti-cancer function in vitro and in vivo . ModPoKI’s modularity allowed us to generate a ∼10,000-member library of TF combinations. Non-viral knockin of a combined BATF-TFAP4 polycistronic construct further enhanced function in vivo . ModPoKI facilitates discovery of complex gene constructs to program cellular functions. Highlights: Modular pooled knockins of hundreds of TF and surface receptor constructs combined with different antigen receptors Chronic stimulation screens discover programs to improve T cell persistence Combinatorial knockin screens with ∼10,000 transcription factor combinations BATF-TFAP4 dual knockin construct improves CAR T cell function in vitro and in vivo
Open AccessModular Pooled Discovery of Synthetic Knockin Sequences to Program Durable Cell Therapies
SUMMARY: Chronic stimulation can cause T cell dysfunction and limit efficacy of cellular immunotherapies. CRISPR screens have nominated gene targets for engineered T cells, but improved methods are required to compare large numbers of synthetic knockin sequences to reprogram cell functions. Here, we developed Modular Pooled Knockin Screening (ModPoKI), an adaptable platform for modular construction of DNA knockin libraries using barcoded multicistronic adaptors. We built two ModPoKI libraries of 100 transcription factors (TFs) and 129 natural and synthetic surface receptors. Over 20 ModPoKI screens across human TCR and CAR T cells in diverse conditions identified a transcription factor AP4 (TFAP4) construct to enhance long-term T cell fitness and anti-cancer function in vitro and in vivo . ModPoKI’s modularity allowed us to generate a ∼10,000-member library of TF combinations. Non-viral knockin of a combined BATF-TFAP4 polycistronic construct further enhanced function in vivo . ModPoKI facilitates discovery of complex gene constructs to program cellular functions. Highlights: Modular pooled knockins of hundreds of TF and surface receptor constructs combined with different antigen receptors Chronic stimulation screens discover programs to improve T cell persistence Combinatorial knockin screens with ∼10,000 transcription factor combinations BATF-TFAP4 dual knockin construct improves CAR T cell function in vitro and in vivo